Aptevo Therapeutics (APVO)
(Delayed Data from NSDQ)
$0.89 USD
-0.05 (-4.81%)
Updated May 10, 2024 04:00 PM ET
After-Market: $0.90 +0.01 (1.12%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Aptevo Therapeutics Inc. [APVO]
Reports for Purchase
Showing records 1 - 20 ( 94 total )
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
4Q23: New ALG.APV-527 Data APVO436/Ven/Aza 1st-Line AML Trial Starts Soon
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology and Medical Device Conference Note
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - 36th Annual Roth Conference, Biotechnology Track, March 17-19
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q23: APVO436 Phase 2 On Deck, ALG.APV527 In Phase 1, Funded Into 4Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: HC Opportunities Conference in NYC on October 12th
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: HC Opportunities Conference in NYC on October 12th
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2Q23: APVO436 Phase 2 To Start, ALG.APV527 Data by YE23, Funded Into 3Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
New Positive Phase 1b APVO436 Data - DoR, Response Rate, Transplant Rate
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
1Q23: Clinical Pipeline Progressing, Funded Into Early 2024
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
4Q22: Clinical Pipeline Progressing, Funded Into Early 2024
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in ALG.APV-527 Phase 1 Trial in 5T4+ Solid Tumors
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
APVO436 Outperforms In Venetoclax Naive AML, Phase 2 Should Start In 2H23
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q22: APVO436 Progressing, New Clinical Trials to Start, Cash to Mid-2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J